Udo-michael M. Goehring
Glattbrugg, ZH, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Intravenous ferric carboxymaltose for iron repletion following acute heart failure in patients with and without diabetes: a subgroup analysis of the randomized AFFIRM-AHF trial.
Journal: Cardiovascular diabetology
Published: February 27, 2023
Ferric Carboxymaltose in Iron-Deficient Patients with Hospitalized Heart Failure and Reduced Kidney Function.
Journal: Clinical journal of the American Society of Nephrology : CJASN
Published: December 09, 2022
Iron deficiency and the effectiveness of the BNT162b2 vaccine for SARS-CoV-2 infection: A retrospective, longitudinal analysis of real-world data.
Journal: PloS one
Published: October 23, 2022
Minimal Clinically Important Differences in 6-Minute Walk Test in Patients With HFrEF and Iron Deficiency.
Journal: Journal of cardiac failure
Published: January 31, 2022
Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency.
Journal: European journal of heart failure
Published: January 17, 2022
Responder analysis for improvement in 6-min walk test with ferric carboxymaltose in patients with heart failure with reduced ejection fraction and iron deficiency.
Journal: European journal of heart failure
Published: December 10, 2021
Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial.
Journal: European journal of heart failure
Published: October 05, 2021
A Pooled Analysis of Serum Phosphate Measurements and Potential Hypophosphataemia Events in 45 Interventional Trials with Ferric Carboxymaltose.
Journal: Journal of clinical medicine
Published: September 29, 2020
Oral ferroportin inhibitor VIT-2763: First-in-human, phase 1 study in healthy volunteers.
Journal: American journal of hematology
Published: October 18, 2019
Anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease (ROBERT): a 16-week, randomised, placebo-controlled trial.
Journal: The Lancet. Respiratory medicine
Published: May 29, 2018
Control of moderate-to-severe asthma with randomized ciclesonide doses of 160, 320 and 640 μg/day.
Journal: Journal of asthma and allergy
Published: March 24, 2017
Randomized Double-Blind Controlled Trial of Roflumilast at Acute Exacerbations of Chronic Obstructive Pulmonary Disease.
Journal: American journal of respiratory and critical care medicine
Published: February 02, 2017
Last Updated: 09/26/2026